New Haven, CTNCT07273838Now EnrollingIRB Ready

Heart Failure Clinical Trial in New Haven, CT

Access cutting-edge heart failure treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Yale University

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access heart failure specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related heart failure treatment provided free

Apply for This New Haven Location

Check if you qualify for this heart failure clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Heart Failure Study in New Haven

The overall objective of this study is to determine whether the addition of SGLT2 inhibitors to usual care in hospitalized patients with heart failure associated acute kidney injury is safe and efficacious. Investigators will assess if SGLT2 inhibition improves a composite cardio-renal outcome (mortality, dialysis, AKI progression, decongestion metrics, heart failure symptoms). Secondary objectives of this study are to compare individual components of the composite outcome as well as changes in biomarkers of kidney injury, inflammation, repair and oxidative stress between those exposed to the SGLT2 inhibitor vs placebo.

Sponsor: Yale University

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged ≥ 18 and ≤ 85 years-old
Diagnosed with heart failure of either preserved or reduced left ventricular function
Have signs of heart failure exacerbation
Ability to take an oral medication
Willing to adhere to the SGLT2i vs placebo regimen

Exclusion Criteria

AKI can be primarily explained by another etiology
Current use of SGLT2 inhibitor or exposure in the past 72 hours
Pregnancy or lactation (pregnancy test prior to enrollment in women of child-bearing age)
Known allergic reactions to components of an SGLT2 inhibitor
Treatment with another investigational drug for heart failure different from or in addition to usual care within the 72 hours preceding AKI
Any individual who meets any of the following criteria will be excluded from participation in this study:
Documented history of ileal conduit (neobladder)
No means of collecting urine such as patients with documented incontinence without indwelling or external urinary catheter
Advanced kidney disease at baseline defined as baseline eGFR \< 25 ml/min/1.73m2
Unexplained hypoglycemia in the past 30 days from enrollment
History of Fournier's gangrene (pelvic necrotizing fasciitis)
History of recurrent urinary tract infection (UTI): defined as documented UTI at least 2x in the preceding 6 months or 3 x in the preceding 12 months
End-stage kidney disease with dialysis requirement
Oliguria: defined as less than 30 ml urine output per hour for more than two consecutive hours or less than 500 ml over the preceding 24 hours
Severe acute kidney injury with indications for dialysis
Current dialysis receipt for acute kidney injury
Comfort measures only
Solid organ transplant on immunosuppression

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT07273838) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Failure Treatment Options in New Haven, CT

If you're searching for heart failure treatment options in New Haven, CT, this clinical trial (NCT07273838) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart failure specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart failure clinical trials near you to find additional studies recruiting in your area.

More Heart Failure Trials in New Haven, CT

See all heart failure clinical trials recruiting in New Haven — not just this study.

Browse Heart Failure Trials in New Haven →

Browse More Trials by Condition

Heart Failure TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT